Akums Drugs enters into exclusive Master Sales Agreement with Caregen

19 Nov 2024 Evaluate

Akums Drugs and Pharmaceuticals has entered into an exclusive Master Sales Agreement with Caregen Company, (Caregen), a leading South Korean company in Nutraceuticals segment. Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement. Further the company shall also undertake the packaging, marketing and selling of Caregen’s line of bulk product under the Caregen’s trademark or Akums’s trademark or of Akums’s Clients trademark.

Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products. 

Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.


Akums Drugs & Pharmaceuticals Share Price

573.15 12.30 (2.19%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.